Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1831 to 1845 of 7615 results

  1. DV7103 for treating cystinuria in people 6 months and over TS ID 10438

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    In development [GID-HST10033] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  3. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652

    Awaiting development [GID-TA11194] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis TS ID 11790

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523

    Awaiting development [GID-TA11114] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development [GID-TA10885] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

    Awaiting development [GID-TA11053] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690

    Awaiting development [GID-TA11073] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

    Awaiting development [GID-TA11049] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

    Awaiting development [GID-TA11048] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

    Awaiting development [GID-TA11011] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

    Awaiting development [GID-TA10967] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development